NCT05475314

Effect of Postbiotic Product on Colonic Barriers in IBS

Name: Clinical Trial NCT05475314
Creator: Nordisk Rebalance A/S
Keywords: IBS - Irritable Bowel Syndrome, ReFerm(R), dietary supplement, clinical trial, Sweden

A Postbiotic Fermented Oat Gruel May Have a Beneficial Effect on the Colonic Mucosal Barrier in Patients With Irritable Bowel Syndrome

Nordisk Rebalance A/S·ClinicalTrials.gov·dietary supplementCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: IBS - Irritable Bowel Syndrome
Drug/Device/Intervention: ReFerm(R)
Study type: Interventional
Intervention type: dietary supplement

Sponsor & location

Primary sponsor: Nordisk Rebalance A/S
Location: Linköping, Sweden

Timeline & enrollment

Phase: N/A
Start date: Dec 01, 2020
End date: Apr 30, 2022
Enrollment: 30 participants

Primary outcome

Intestinal permeability

Summary

Impaired intestinal permeability and microbial dysbiosis are important pathophysiological mechanisms underlying irritable bowel syndrome (IBS). ReFerm®, also called Profermin®, is a postbiotic product of oat gruel fermented with Lactobacillus plantarum 299v. In this experimental study, we investigated whether ReFerm® has a beneficial effect on the intestinal epithelial barrier function in patients with IBS.

ICD-10 classifications

Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndromeIrritable bowel syndrome with predominant diarrhoea [IBS-D]Irritable bowel syndrome with mixed bowel habits [IBS-M]Other and unspecified irritable bowel syndrome

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05475314
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05475314 through Pure Global AI's free database. This phase not specified trial is sponsored by Nordisk Rebalance A/S and is currently Completed. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.